Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (40): 7577-7580.doi: 10.3969/j.issn.1673-8225.2011.40.039

Previous Articles     Next Articles

Gene-modified stem cell therapy for ischemic heart disease

Yao Yong-zhao, Ma Xiang   

  1. Department of Coronary Heart Disease, First Affiliated Hospital of Xinjiang Medical University, Urumqi  830000, Xinjiang Uygur Autonomous Region, China
  • Received:2011-02-24 Revised:2011-05-25 Online:2011-10-01 Published:2011-10-01
  • Contact: Ma Xiang, Associate chief physician, Master’s supervisor, Department of Coronary Heart Disease, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, Xinjiang Uygur Autonomous Region, China maxiangxj@sohu.com
  • About author:Yao Yong-zhao★, Studying for master’s degree, Department of Coronary Heart Disease, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, Xinjiang Uygur Autonomous Region, China tony0352@163.com
  • Supported by:

    the Natural Science Foundation of Xinjiang Uygur Autonomous Region, No. 2009211B20*; the Key Project for Science and Technology Research in Xinjiang Uygur Autonomous Region, Ministry of Education, No. 209137*

PDF

407

Abstract:

BACKGROUND: Genetically modified stem cells in treating ischemic heart disease is one of the focus area of cardiovascular research after the simple stem cells therapy, and it may open a new and useful way for treatment of ischemic heart disease.
OBJECTIVE: To summarize the situation and progression about gene-modified stem cell therapy for ischemic heart disease at present.
METHODS: Databases of CNKI and Pubmed (2000-01/2010-12) were used to search the related articles about gene-modified stem cell therapy of ischemic heart disease. The keywords were “genetic, stem cells, myocardial infarction”. Finally, 29 articles related to genetically modified stem cells in treating ischemic heart disease were included.
RESULTS AND CONCLUSION: For the purpose of improving stem cells effect on ischemic heart disease, different gene are applied to modify stem cells and their surrounding environment to improve the stem cells and the corresponding traits in order to promote transplanted stem cell viability, promote angiogenesis of myocardial ischemia and peripheral tissues, improve vascular compliance, increase the coupling with host cardiomyocytes, and enhance the homing of stem cells. With the development of gene technology and stem cell application, stem cell therapy may be widely used in clinical treatment of ischemic heart disease.

CLC Number: